HF-158K1 by HighField Biopharmaceuticals for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

HF-158K1 is under clinical development by HighField Biopharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer).

This Big American Cannabis Market Is Booming

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

July 12, 2024

California lawmakers debate sending local health inspectors into immigration facilities

Covid-19, mumps, and chickenpox outbreaks. Contaminated water, moldy food, and air ducts spewing black dust.

July 30, 2024

AstraZeneca makes $1B deal for Gracell and its cell therapies, adding to China ties

AstraZeneca will pay $1 billion to buy China-US cell therapy company Gracell Biotechnologies, adding to a rush of deals that have been announced at the

December 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.